Table 5. Quality of life outcomes for... | American Society of Hematology

Table 5.

Quality of life outcomes for studies grouped by baseline Hb levels: comparisons between control and epoetin-treated study arms

Study	Treatment arm	No.evaluable for transfusion	No.evaluable for QOL	Overall QOL		Energy level		Daily activities		Other QOL
Study	Treatment arm	No.evaluable for transfusion	No.evaluable for QOL	% change	P	% change	P	% change	P	Measure^5-150	% change	P
Mean/median baseline Hb below 10 g dL
Kurz et al¹³	Control	12	12					−14.5		Well-being	4.0
	Epoetin	23	23					−6.5	NS	Well-being	−0.1	NS
	Control	12	12							Physical ability	8.0
	Epoetin	23	23							Physical ability	8.3	NS
	Control	12	12							Social activities	12.8
	Epoetin	23	23							Social activities	1.0	NS
Henry et al¹²	Control	61	40	0.2		6.2		0.7
	Epoetin	64	46	11.0	.013	8.8	NS	8.2	NS
Littlewood et al¹⁵	Control	115	108	NA		−5.8		−6.0
	Epoetin	244	227	NA	< .01	7.8	< .001	7.3	< .01
	Control	115	90							FACT-An: anemia	−9.4
	Epoetin	244	200							FACT-An: anemia	14.4	< .01
	Control	115	90							FACT-An: fatigue	−4.2
	Epoetin	244	200							FACT-An: fatigue	5.7	< .01
	Control	115	?							SF-36	NA
	Epoetin	244	?							SF-36	NA	NS
Leon et al⁶⁰	Control	25	25							Karnofsky PS	1.4
	Epoetin	25	25							Karnofsky PS	8.6	< .05
Mean/median baseline Hb above 12 g/dL
Sweeney et al⁶²	Control	24	24	6.3
	Epoetin	22	22	19.1	.15, NS
Welch et al⁶⁵	Control	15	?15	NA		NA		NA
	Epoetin	15	?15	NA	NS	NA	NS	NA	NS
Del Mastro et al⁶⁴	Control	31	26							PDI score	2.3
	Epoetin	31	27							PDI score	6.0	NS

Study	Treatment arm	No.evaluable for transfusion	No.evaluable for QOL	Overall QOL		Energy level		Daily activities		Other QOL
Study	Treatment arm	No.evaluable for transfusion	No.evaluable for QOL	% change	P	% change	P	% change	P	Measure^5-150	% change	P
Mean/median baseline Hb below 10 g dL
Kurz et al¹³	Control	12	12					−14.5		Well-being	4.0
	Epoetin	23	23					−6.5	NS	Well-being	−0.1	NS
	Control	12	12							Physical ability	8.0
	Epoetin	23	23							Physical ability	8.3	NS
	Control	12	12							Social activities	12.8
	Epoetin	23	23							Social activities	1.0	NS
Henry et al¹²	Control	61	40	0.2		6.2		0.7
	Epoetin	64	46	11.0	.013	8.8	NS	8.2	NS
Littlewood et al¹⁵	Control	115	108	NA		−5.8		−6.0
	Epoetin	244	227	NA	< .01	7.8	< .001	7.3	< .01
	Control	115	90							FACT-An: anemia	−9.4
	Epoetin	244	200							FACT-An: anemia	14.4	< .01
	Control	115	90							FACT-An: fatigue	−4.2
	Epoetin	244	200							FACT-An: fatigue	5.7	< .01
	Control	115	?							SF-36	NA
	Epoetin	244	?							SF-36	NA	NS
Leon et al⁶⁰	Control	25	25							Karnofsky PS	1.4
	Epoetin	25	25							Karnofsky PS	8.6	< .05
Mean/median baseline Hb above 12 g/dL
Sweeney et al⁶²	Control	24	24	6.3
	Epoetin	22	22	19.1	.15, NS
Welch et al⁶⁵	Control	15	?15	NA		NA		NA
	Epoetin	15	?15	NA	NS	NA	NS	NA	NS
Del Mastro et al⁶⁴	Control	31	26							PDI score	2.3
	Epoetin	31	27							PDI score	6.0	NS

“Higher quality” trials in bold font; nonrandomized studies in italics. Data from Seidenfeld et al.3 ^(Tab22)

FACT-An indicates Functional Assessment of Cancer Therapy—Anemia; SF-36, Short Form 36; PS, performance status; and PDI, Psychological Distress Inventory.

F5-150

In order to accommodate several “Other” QoL instruments or different statistical testing results, study control and treatment arms may be listed more than once.

View Large

This Feature Is Available To Subscribers Only